“…Recently, Escherichia coli has proven to be an excellent biocatalyst platform for metabolic engineering (Gupta, Reizman, Reisch, & Prather, ; Long, Au, Sandoval, Gebreselassie, & Antoniewicz, ), and much of the work focused on improving malate production has sought to redirect carbon flow into malate. However, as the malate biosynthesis pathway is located in the cytoplasm, these studies have focused on cytoplasmic engineering, including of the one‐step synthesis pathway (Dong et al, ), rTCA pathway (Moon, Hong, Kim, & Lee, ; Zhang, Wang, Shanmugam, & Ingram, ), and noncyclic glyoxylate pathway (Gao et al, ). Thus, one of the challenges in metabolic engineering for the production of malate involves enhancing the transmission efficiency of intermediate metabolites in metabolic or synthetic pathways by limiting metabolic crosstalk.…”